ÈËÆÞÖгöÊÓƵ

Ahmad S. Halwani
( out of 34 reviews )

Ahmad S. Halwani, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
Salt Lake City
801-585-2626

  • Dr. Ahmad Halwani is an Assistant Professor of Medicine in the Division of Hematology and Hematologic Malignancies in the Department of Internal Medicine at the ÈËÆÞÖгöÊÓƵ of Utah and a clinical investigator at the Huntsman Cancer Institute (HCI). He is also a staff physician and clinical researcher at the George E Whalen Veterans ÈËÆÞÖгöÊÓƵ Administration (VHA) in Salt Lake City. Dr. Halwani’s practice at Huntsman Cancer Institute focuses on lymphoid malignancies, specifically Lymphoma and Chronic Lymphocytic Leukemia (CLL). Dr. Halwani was also responsible for leading an effort to establish the first lymphoid malignancy focused clinic at the George E Whalen VHA where Veterans with Lymphoma and CLL can receive sub-specialty focused care.


    For questions regarding Dr. Halwani's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at www.huntsmancancer.org or (801) 585-6906.

    Specialties

    Board Certification

    American Board of Internal Medicine (Sub: Medical Oncology)
    Educational Commission for Foreign Medical Graduates

    Patient Rating

    4.7 /5
    ( out of 34 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    September 29, 2024
    HUNTSMAN CANCER CENTER

    Dr. Halwani is wonderful. I'm grateful to ge in his care.

    September 29, 2024
    HUNTSMAN CANCER CENTER

    Dr Halwani is very caring and always makes sure I understand everything.

    June 30, 2024
    HUNTSMAN CANCER CENTER

    Dr. Halwani is a thoughtful, experienced and caring physician. My husband has been seeing him regularly from his initial non-Hopkins Lymphoma in 2011. Doctor listens carefully and engages one's confidence immediately. We highly recommend Dr. Halwani.

    June 29, 2024
    HUNTSMAN CANCER CENTER

    The best doctor I have ever had.

    June 17, 2024
    HUNTSMAN CANCER CENTER

    Doctor Halwani has been with me for 12 years He is the best.That is why I`m still alive.

    June 01, 2024
    HUNTSMAN CANCER CENTER

    Dr Halwani is a wonderful anthologist and great at answering all of my questions as well as explaining all the proceedures and what all of the drugs were used for and their effects on me I would recommend him to anyone going through cancer treatment

    March 24, 2024
    HUNTSMAN CANCER CENTER

    Dr. Halwani is a wonderful, caring physician.

    March 11, 2024
    HUNTSMAN CANCER CENTER

    It's my first experience with Dr Halwani or any oncologist but he has given me a great feeling of confidence in being in his care and providing me with the best treatments for this next step in my life

    February 25, 2024
    HUNTSMAN CANCER CENTER

    I'm very happy Dr. Halwani is my doctor. He makes me feel so at ease. I trust him completely in making the right decisions about me.

    See More Patient Comments

  • Dr. Ahmad Halwani is an Assistant Professor of Medicine in the Division of Hematology and Hematologic Malignancies in the Department of Internal Medicine at the ÈËÆÞÖгöÊÓƵ of Utah and a clinical investigator at the Huntsman Cancer Institute (HCI). He is also a staff physician and clinical researcher at the George E Whalen Veterans ÈËÆÞÖгöÊÓƵ Administration (VHA) in Salt Lake City. Dr. Halwani’s practice at Huntsman Cancer Institute focuses on lymphoid malignancies, specifically Lymphoma and Chronic Lymphocytic Leukemia (CLL). Dr. Halwani was also responsible for leading an effort to establish the first lymphoid malignancy focused clinic at the George E Whalen VHA where Veterans with Lymphoma and CLL can receive sub-specialty focused care.


    For questions regarding Dr. Halwani's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at or (801) 585-6906.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine (Sub: Medical Oncology)
    Educational Commission for Foreign Medical Graduates

    Education history

    Fellowship Medical Oncology - ÈËÆÞÖгöÊÓƵ of Iowa Hospitals & Clinics Fellow
    Allergy and Immunology - ÈËÆÞÖгöÊÓƵ of Iowa Hospitals & Clinics Fellow
    Residency Internal Medicine - ÈËÆÞÖгöÊÓƵ of Iowa Hospitals & Clinics Resident
    Medicine - American ÈËÆÞÖгöÊÓƵ of Beirut M.D.
    Undergraduate Biology with High Distinction - American ÈËÆÞÖгöÊÓƵ of Beirut B.S.

    Selected Publications

    Journal Article

    1. Rasmussen KM, Patil V, Li C, Yong C, Appukkuttan S, Grossman JP, Jhaveri J, Halwani AS (2023). Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer. JAMA Netw Open, 6(10), e2337272. ()
    2. Burningham Z, Jackson GL, Kelleher JL, Morris I, Stevens MB, Cohen J, Maloney G, Sauer BC, Halwani AS, Chen W, Vaughan CP (2023). Use of a Medication Safety Audit and Feedback Tool in the Emergency Department Is Affected by Prescribing Characteristics. Appl Clin Inform, 14(4), 684-692. ()
    3. Chien HC, Morreall D, Patil V, Rasmussen KM, Yong C, Li C, Passey DG, Burningham Z, Sauer BC, Halwani AS (2021). Treatment Patterns and Outcomes in a Nationwide Cohort of Older and Younger Veterans with Waldenström Macroglobulinemia, 2006-2019. Cancers (Basel), 13(7). ()
    4. Li C, Patil V, Rasmussen KM, Yong C, Chien HC, Morreall D, Humpherys J, Sauer BC, Burningham Z, Halwani AS (2021). Predicting Survival in Veterans with Follicular Lymphoma Using Structured Electronic ÈËÆÞÖгöÊÓƵ Record Information and Machine Learning. Int J Environ Res Public ÈËÆÞÖгöÊÓƵ, 18(5). ()
    5. Chien HC, Morreall D, Patil V, Rasmussen KM, Li C, Yong CM, Burningham Z, Masaquel A, Halloran M, De Long-Sieg E, Schulz M, Sauer BC, Halwani AS (2020). Real-world practice patterns and outcomes in Veterans with relapsed/refractory diffuse large B-cell lymphoma. Future Oncol, 17(4), 411-422. ()
    6. Passey DG, Healy R, Qualls J, Halwani A, Sauer BC (2020). Pharmacist-led collaborative medication management programs for oral antineoplastic therapies: A systematic literature review. J Am Pharm Assoc (2003), 61(3), e7-e18. ()
    7. Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kim YH, Mehta-Shah N, Olsen EA, Pro B, Rajguru SA, Rozati S, Said J, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar H (2020). NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021. J Natl Compr Canc Netw, 18(11), 1460-1467. ()
    8. Halwani AS, Rasmussen KM, Patil V, Morreall D, Li C, Yong C, Burningham Z, Dawson K, Masaquel A, Henderson K, DeLong-Sieg E, Sauer BC (2020). Maintenance rituximab in Veterans with follicular lymphoma. Cancer Med, 9(20), 7537-7547. ()
    9. Richter Lagha R, Burningham Z, Sauer BC, Leng J, Peters C, Huynh T, Patel S, Halwani AS, Kramer BJ (2020). Usability Testing a Potentially Inappropriate Medication Dashboard: A Core Component of the Dashboard Development Process. Appl Clin Inform, 11(4), 528-534. ()
    10. Mehta-Shah N, Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Fisher K, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Lunning MA, Mehta A, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar H, Kim YH (2020). NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020. J Natl Compr Canc Netw, 18(5), 522-536. ()
    11. Rasmussen KM, Patil V, Burningham Z, Yong C, Sauer BC, Halwani AS (2020). Atrial Fibrillation and Bleeding in Patients With Chronic Lymphocytic Leukemia Treated with Ibrutinib in the Veterans ÈËÆÞÖгöÊÓƵ Administration. Fed Pract, 37(Suppl 2), S44-S49. ()
    12. Halwani AS, Rasmussen KM, Patil V, Li CC, Yong CM, Burningham Z, Gupta S, Narayanan S, Lin SW, Carroll S, Mhatre SK, Graff JN, Dreicer R, Sauer BC (2019). Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer. Urol Oncol, 38(1), 1.e1-1.e10. ()
    13. Walsh JA, Pei S, Penmetsa GK, Sauer BC, Patil V, Walker JH, Clewell J, Douglas KM, Clegg DO, Cannon GW, Halwani A (2019). Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis. J Manag Care Spec Pharm, 25(11), 1218-1228. ()
    14. Burningham Z, Chen W, Sauer BC, Richter Lagha R, Hansen J, Huynh T, Patel S, Leng J, Halwani A, Kramer BJ (2019). VA Geriatric Scholars Program's impact on prescribing potentially inappropriate medications. Am J Manag Care, 25(9), 425-430. ()
    15. Peters CB, Hansen JL, Halwani A, Cho ME, Leng J, Huynh T, Burningham Z, Caloyeras J, Matsuda T, Sauer BC (2019). Validation of Algorithms Used to Identify Red Blood Cell Transfusion Related Admissions in Veteran Patients with End Stage Renal Disease. EGEMS (Wash DC), 7(1), 23. ()
    16. Elkeeb D, Hopkins Z, Miles RR, Halwani A, Wada D (2019). Ominous cutaneous presentation of acute myeloid leukemia without peripheral blood involvement upon initial presentation and relapse: case report and literature review. Eur J Dermatol, 28(6), 809-817. ()
    17. Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M, MAVORIC Investigators (2018). Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol, 19(9), 1192-1204. ()
    18. Burningham Z, Leng J, Peters CB, Huynh T, Halwani A, Rupper R, Hicken B, Sauer BC (2018). Predicting Psychiatric Hospitalizations among Elderly Veterans with a History of Mental ÈËÆÞÖгöÊÓƵ Disease. EGEMS (Wash DC), 6(1), 7. ()
    19. Horwitz SM, Ansell SM, Ai WZ, Barnes J, Barta SK, Choi M, Clemens MW, Dogan A, Greer JP, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Kim YH, Lunning MA, Mehta A, Mehta-Shah N, Oki Y, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shustov A, Sokol L, Torka P, Wilcox R, William B, Zain J, Dwyer MA, Sundar H (2018). NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018. J Natl Compr Canc Netw, 16(2), 123-135. ()
    20. Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Perales MA, Avigdor A, Halwani AS, Houot R, Marchand T, Dhedin N, Lescaut W, Thiebaut-Bertrand A, Franois S, Stamatoullas-Bastard A, Rohrlich PS, Labussire Wallet H, Castagna L, Santoro A, Bachanova V, Bresler SC, Srivastava A, Kim H, Pesek E, Chammas M, Reynolds C, Ho VT, Antin JH, Ritz J, Soiffer RJ, Armand P (2017). Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood, 129(10), 1380-1388. ()
    21. Vrontikis A, Carey J, Gilreath JA, Halwani A, Stephens DM, Sweetenham JW (2016). Proposed Algorithm for Managing Ibrutinib-Related Atrial Fibrillation. Oncology (Williston Park), 30(11), 970-4, 980-1, C3. ()
    22. Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, Dhodapkar M, Avigan D, Chapuy B, Ligon AH, Freeman GJ, Rodig SJ, Cattry D, Zhu L, Grosso JF, Bradley Garelik MB, Shipp MA, Borrello I, Timmerman J (2016). Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol, 34(23), 2698-704. ()
    23. McPherson JP, Vrontikis A, Sedillo C, Halwani AS, Gilreath JA (2016). Pralatrexate Monitoring Using a Commercially Available Methotrexate Assay to Avoid Potential Drug Interactions. Pharmacotherapy, 36(2), e8-e11. ()
    24. Colonna S, Halwani A, Ying J, Buys S, Sweeney C (2015). Women with breast cancer in the Veterans ÈËÆÞÖгöÊÓƵ Administration: demographics, breast cancer characteristics, and trends. Med Care, 53(4 Suppl 1), S149-55. ()
    25. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P (2015). PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med, 372(4), 311-9. ()
    26. Nelson SD, Lu CC, Teng CC, Leng J, Cannon GW, He T, Zeng Q, Halwani A, Sauer B (2015). The use of natural language processing of infusion notes to identify outpatient infusions. Pharmacoepidemiol Drug Saf, 24(1), 86-92. ()
    27. Ontiveros EP, Halwani A, Stunz LL, Kamberos N, Olivier AK, Janz S, Bishop GA (2014). A new model of LMP1-MYC interaction in B cell lymphoma. Leuk Lymphoma, 55(12), 2917-23. ()
    28. Han SS, Tompkins VS, Son DJ, Kamberos NL, Stunz LL, Halwani A, Bishop GA, Janz S (2013). Piperlongumine inhibits LMP1/MYC-dependent mouse B-lymphoma cells. Biochem Biophys Res Commun, 436(4), 660-5. ()
    29. Halwani AS, Link BK (2011). Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma. Expert Rev Anticancer Ther, 11(3), 443-55. ()
    30. Racila E, Link BK, Weng WK, Witzig TE, Ansell S, Maurer MJ, Huang J, Dahle C, Halwani A, Levy R, Weiner GJ (2008). A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res, 14(20), 6697-703. ()

    Letter

    1. Chien HC, Morreall D, Patil V, Rasmussen KM, Yong CM, Li CY, Passey DG, Burningham Z, Sauer BC, Halwani AS (2021). Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019. [Letter to the editor]. Am J Hematol, 96(6), E184-E187. ()
    2. Laggis CW, Lamb A, Secrest AM, Ufkes N, Halwani AS, Tao R, Gaffney D, Miles RR, Florell SR, Wada D (2020). Favourable outcomes in folliculotropic mycosis fungoides after multimodality treatment in a single institution. [Letter to the editor]. J Eur Acad Dermatol Venereol, 35(1), e42-e45. ()

    Abstract

    1. Kim YH, Bagot M, Eradat HA, Carson KR, Greer JP, Kim EJ, Kuzel T, Hughey LC, Poligone B, Lansigan F, Zinzani PL, Grandinetti LM, Procu P, Shustov AR, Korman NJ, Halwani A, Sokol L, Duvic M (01012014). Phase 3 study of anti-CCR4 monoclonal antibody mogamulizumab vs vorinostat in relapsed or refractory cutaneous t-cell lymphoma (CTCL). [Abstract]. J Clinical Oncology American Society of Clinicial Oncology annual meeting.
    2. Lesokhin A, Gutierrez M, Halwani A, Ansell SM, Armand P, Borrello I, Segota ZE, Cohen AD, Talpaz M, Cattry D, Turner T, Mezes M, Hartman C, Gupta A, Kim SY, Wigginton JM, Timmerman JM (01012014). A Phase 1 Dose Escalation Study Evaluating the Effects of Nivolumab (anti-PD-1; BMS-936558) in Patients with Select Relapsed or Refractory Hematologic Malignancies. [Abstract]. J Clinical Oncology American Society of Clinicial Oncology annual meeting.
    3. Halwani A, Stunz S, Hu L, Janz S, Bishop G (2010). A new mouse lymphoma model, the iMycEµ-LMP1 transgenic mouse, suggests collaboration of LMP1 and Myc in lymphomagenesis. Poster Presentation; ÈËÆÞÖгöÊÓƵ of Iowa Carver College of Medicine, College of Pharmacy, College of Public ÈËÆÞÖгöÊÓƵ, Institute for Clinical and Translational Science and VA ÈËÆÞÖгöÊÓƵ System Research Week. [Abstract].
    4. Halwani A, Ballas Z (2009). Progression of Selective IgM Deficiency to Common Variable Immunodeficiency. Journal of Allergy and Clinical Immunology. Poster Presentation, AAAAI annual meeting [Abstract]. 123(2, Supplement 1), S89.
    5. Halwani A (2008). Eczematous Rash, Elevated IgE & Recurrent Infections. Presented at the Clinical Immunology Society Primary Immunodeficiency Summer School. [Abstract].
    6. Halwani A, Ballas Z (2008). Delayed Recovery of T Cell Response Post Cyclosporin Therapy. Journal of Allergy and Clinical Immunology. Poster Presentation, AAAAI annual meeting. [Abstract]. 121(2, Supplement 1), S87.
    7. Halwani A, Gingrich R (2005). An Unusual Tonsillitis. American College of Physicians, Iowa Chapter, Associates Clinical Vignette Competition. [Abstract].